February 01, 2023
Medicare: Part B Step Therapy program updates
Intravenous iron replacement therapy
Effective for dates of service starting Feb. 1, 2023, Feraheme® (ferumoxytol injection) will move to a preferred status in the UnitedHealthcare® Medicare Advantage Part B Step Therapy program. We will no longer require prior authorization for Feraheme for Medicare and Retirement plan members.
VEGF Inhibitors class updates
As a reminder, we recently made changes to the Intravitreal Vascular Endothelial Growth Factor (VEGF) Inhibitors class, including:
- Effective Jan. 1, 2023, all Intravitreal VEGF Inhibitors except compounded Avastin® require prior authorization for all conditions, not just for neovascular (wet) age-related macular degeneration (AMD)
- Eylea® is preferred:
- After compounded Avastin for AMD
- For all other retinal conditions (non-AMD diagnoses)
Questions?
For questions related to the Part B Step Therapy program and the corresponding policy, call the Provider Services number on the member’s health care ID card.
For questions about prior authorizations, call 888-397-8129.
